---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-041062"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2021-08-09T23:59:59+00:00"
generated_at: "2026-06-29T19:17:47.834480+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Clene appoints Dr. Vallerie McLaughlin as independent director, effective August 5, 2021

## Summary
- Appointed Vallerie V. McLaughlin, M.D. as Class III director and member of Nominating and Corporate Governance Committee.
- Received option award for 45,000 shares at $9.37 exercise price, vesting in 36 monthly installments.
- Also received immediate options valued at $11,000 (Board $10,000 + committee $1,000) at $9.37 exercise price.
- Dr. McLaughlin is professor at University of Michigan, expert in pulmonary hypertension rare disease trials.
- She becomes the seventh independent director on the seven-member board.

## SEC filing metadata
- accession: 0001213900-21-041062
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2021-08-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000121390021041062/0001213900-21-041062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000121390021041062/ea145457-8k_cleneinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-041062
- JSON: https://secwatch.observer/filing/0001213900-21-041062.json
- Plain text: https://secwatch.observer/filing/0001213900-21-041062.txt

## Key facts
- Executive change
  Vallerie V. McLaughlin, M.D. was appointed as Director at Clene Inc..
  - Action: appointed
  - Role: Director
  source text: On August 5, 2021, the Board of Directors (the “Board”) of Clene Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Vallerie V. McLaughlin, M.D. as a member of the Board, effective August 5, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822791/000121390021041062/0001213900-21-041062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.